Treatment With Revita
Revita, a new revolutionary treatment was developed by Fractyl Laboratories, Inc., a U.S.-based company, to make the body to absorb and process more sugar by burning the gut. The scientists are using a balloon of size less than rice grain in this process. The treatment will take 90 minutes and will be performed under sedation.
The scientists think that new cells to secrete hormones can be formed by burning non-hormone secreting cells. The new cells can secrete more hormones and improve the absorption of glucose.
The University College Hospital, London is going to perform the first Revita DMR procedure. But the scientists could not confirm the relief from diabetes after the treatment.
Treatment With LixiLan From Sanofi
France based Sanofi in collaboration with Zealand Pharma has developed a new diabetes combination therapy drug, LixiLan. The drug has received the approval in some countries with the trade name Lyxumia.
Two trials in phase III were conducted with the LixiLan, LixiLan-O and LixiLan-L. The clinical trial was to check the efficacy and safety of the Sanofi's once-a-day single injection and a combination drug for a period of 30 weeks.
The trial has indicated a better control of HbA1c with LixiLan from the baseline compared with glargine and lixisenatide. The clinical trials of LixiLan diabetes drug are successful. As reported by Sanofi, the side effects are.
The results of both the trials were included in the regulatory submissions in the US and Europe. FDA approval is expected in August and the approval from the European Medicines Agency (EMA) is expected during the next year.
Trials Of ACCORDION
The ACCORDION trial was based on 1,310 individuals with type 2 diabetes (T2D) and diabetic retinopathy (related to eye and vision). This trial is a continuation of the ACCORD trial which started four years ago.
The development of diabetic retinopathy was studied on individuals who have received intensive blood glucose therapy and keeping normal blood glucose levels even after four years.
The study shows that an individual can get positive and long-term effects on the small blood vessels with tight control on glycemic levels.
Emily Chew, M.D., the lead author of the study, says that normal blood sugar (glucose) levels are good for the health of the eye. The study was published in Diabetes Care.
A Study On Automated OCL Insulin System
The study was conducted on Medtronic Android-based PID IFB closed loop blood glucose control system for the practical use during multiple nights at a diabetes camp. The product contains.
The study shows.
The study was conducted by Trang Ly, Ph.D., The study was published in the Diabetes Technology & Therapeutics (DTT).
Benefits With Yogurt
A study by Harvard School of Public Health has found that increased consumption of yogurt can lower the risk of type 2 diabetes (T2D). The daily consumption of 28 grams of yogurt can lower the risk of type 2 diabetes (T2D) by 18 percent.
Yogurt is rich with elements that can help us in regulating the digestion and intestinal function. They are.
Usability Study Of CONTOUR NEXT ONE
Ascensia Diabetes Care is the manufacture of CONTOUR NEXT ONE glucose monitoring systems. A study by Dr. Timothy Bailey (AMCR Institute, San Diego), the lead investigator, to assess the usability of CONTOUR NEXT ONE blood glucose meter on 43 individuals suffering from type 1 diabetes (T1D) or type 2 diabetes (T2D). The study shows.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.